OnKure Therapeutics Stock (NASDAQ:OKUR)

Ownership Financials Chart

Previous Close

$4.19

52W Range

$1.91 - $5.38

50D Avg

$4.28

200D Avg

$3.29

Market Cap

$58.11M

Avg Vol (3M)

$341.35K

Beta

0.28

Div Yield

-

OKUR Company Profile

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

46

IPO Date

Apr 08, 2021

Website

OKUR Performance

OKUR Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-62.95M	$-54.39M	$-36.93M
Net Income	-	$-52.67M	$-35.31M
EBITDA	$-62.95M	$-51.71M	$-34.75M
Basic EPS	$-4.40	$-3.95	$-2.65
Diluted EPS	$-4.40	$-3.95	$-2.65

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
MRSN	Mersana Therapeutics, Inc.
FGEN	FibroGen, Inc.
TPST	Tempest Therapeutics, Inc.
BRNS	Barinthus Biotherapeutics plc
XLO	Xilio Therapeutics, Inc.
PDSB	PDS Biotechnology Corporation
ALGS	Aligos Therapeutics, Inc.